These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 38002585)
41. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study. Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698 [TBL] [Abstract][Full Text] [Related]
42. Major Oncogenic Drivers and Their Clinicopathological Correlations in Sporadic Childhood Papillary Thyroid Carcinoma in Belarus. Rogounovitch TI; Mankovskaya SV; Fridman MV; Leonova TA; Kondratovitch VA; Konoplya NE; Yamashita S; Mitsutake N; Saenko VA Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282777 [TBL] [Abstract][Full Text] [Related]
43. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer. Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368 [TBL] [Abstract][Full Text] [Related]
44. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea. Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609 [TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Koperek O; Kornauth C; Capper D; Berghoff AS; Asari R; Niederle B; von Deimling A; Birner P; Preusser M Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144 [TBL] [Abstract][Full Text] [Related]
46. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651 [TBL] [Abstract][Full Text] [Related]
47. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775 [TBL] [Abstract][Full Text] [Related]
48. Correlations between Molecular Landscape and Sonographic Image of Different Variants of Papillary Thyroid Carcinoma. Lewiński A; Adamczewski Z; Zygmunt A; Markuszewski L; Karbownik-Lewińska M; Stasiak M J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31717363 [TBL] [Abstract][Full Text] [Related]
49. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508 [TBL] [Abstract][Full Text] [Related]
50. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas. Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744 [TBL] [Abstract][Full Text] [Related]
51. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956 [TBL] [Abstract][Full Text] [Related]
52. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937 [TBL] [Abstract][Full Text] [Related]
53. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases. Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878 [TBL] [Abstract][Full Text] [Related]
54. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218 [TBL] [Abstract][Full Text] [Related]
55. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011 [TBL] [Abstract][Full Text] [Related]
56. Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAF Poyrazoğlu Ş; Bundak R; Baş F; Yeğen G; Şanlı Y; Darendeliler F J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):185-193. PubMed ID: 28077340 [TBL] [Abstract][Full Text] [Related]
57. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120 [TBL] [Abstract][Full Text] [Related]
58. Risk and Prognostic Factors for BRAF Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194 [TBL] [Abstract][Full Text] [Related]
59. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAF Hardee S; Prasad ML; Hui P; Dinauer CA; Morotti RA Pediatr Dev Pathol; 2017 Jun; 20(3):206-212. PubMed ID: 28521635 [TBL] [Abstract][Full Text] [Related]
60. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]